

# **Therapy of Diabetes Mellitus**

**Yacoub Irshaid MD, PhD, ABCP**  
**Department of Pharmacology**

# Therapy of Diabetes Mellitus

- **Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders characterized by hyperglycemia.**
- **It is associated with abnormalities in carbohydrate, fat, and protein metabolism.**
- **It may result in chronic complications including microvascular, macrovascular, and neuropathic disorders.**

# Therapy of Diabetes Mellitus

- **DM is the leading cause of blindness and end-stage renal disease.**
- **It may result in lower extremity amputations, and cardiovascular events.**

**TABLE 30-2 Type 1 and Type 2 Diabetes Mellitus**

	<b>TYPE 1</b>	<b>TYPE 2</b>
<b>Etiology</b>	Autoimmune destruction of pancreatic $\beta$ -cells	Insulin resistance, with inadequate $\beta$ -cell function to compensate
<b>Insulin levels</b>	Absent or negligible	Typically higher than normal
<b>Insulin action</b>	Absent or negligible	Decreased
<b>Insulin resistance</b>	Not part of syndrome but may be present (e.g., in obese patients)	Yes
<b>Age of onset</b>	Typically <30 years	Typically >40 years
<b>Acute complications</b>	Ketoacidosis Wasting	Hyperglycemia (can lead to hyperosmotic seizures and coma)
<b>Chronic complications</b>	Neuropathy Retinopathy Nephropathy Peripheral vascular disease Coronary artery disease	Same as type 1
<b>Pharmacologic interventions</b>	Insulin	A number of drug classes are available, including insulin if other therapies fail

Type 1 and type 2 diabetes mellitus are both associated with increased blood glucose levels, but the two diseases result from distinct pathophysiologic pathways. In type 1 diabetes mellitus, there is an absolute lack of insulin secondary to autoimmune destruction of pancreatic  $\beta$ -cells. The etiology of type 2 diabetes is less well understood but seems to involve impaired insulin sensitivity and an inadequate level of compensatory insulin production by pancreatic  $\beta$ -cells. Although type 1 and type 2 diabetes have different acute complications (*see text*), they share similar chronic complications. Insulin is the primary pharmacologic intervention for type 1 diabetes, while type 2 diabetes can be treated with a number of different agents.

# Drug-induced Diabetes Mellitus

1. **Pyriminil (Vacor) (rodenticide) – loss of pancreatic  $\beta$ -cells.**
2. **Pentamidine – cytotoxic effect on pancreatic  $\beta$ -cells (type 1).**
3. **Nicotinic acid (Niacin) – insulin resistance.**
4. **Glucocorticoids – Metabolic effects and insulin antagonism.**
5. **Thyroid hormones – increase hepatic glucose production.**
6. **Growth hormone - reduces insulin sensitivity resulting in mild hyperinsulinemia, and increased blood glucose levels**
7. **Diazoxide: inhibition of insulin secretion.**

# Drug-induced Diabetes Mellitus

8.  $\beta$ -adrenergic agonists – glycogenolysis, and gluconeogenesis.
9. Thiazides – hypokalemia-induced inhibition of insulin release.
10. Interferone –  $\beta$ -cell destruction (type 1)
11. Chronic alcoholism - insulin insensitivity and pancreatic  $\beta$ -cell dysfunction.
12. Cyclosporine – suppresses insulin production and release. It may produce insulin resistance.

# Drug-induced Diabetes Mellitus

- 13. HIV protease inhibitors - insulin resistance with insulin deficiency relative to hyperglucagonemia.**
- 14. Atypical antipsychotics (clozapine and olanzapine) – weight gain and insulin resistance.**
- 15. Megestrol acetate – insulin resistance.**
- 16. Others ...**

# Therapy of Diabetes Mellitus

## Desired Outcome:

The primary goals of DM management are:

1. To reduce the risk of microvascular and macrovascular disease complications.
2. To ameliorate symptoms.
3. To reduce mortality.
4. To improve quality of life.
5. To minimize weight gain and hypoglycemia.

# Therapy of Diabetes Mellitus

- **Early diagnosis** and **treatment to near-normoglycemia** reduces the risk of developing microvascular disease complications (retinopathy, nephropathy, and neuropathy).

# Therapy of Diabetes Mellitus

- Aggressive management of cardiovascular risk factors: smoking cessation, treatment of dyslipidemia, intensive blood pressure control, and antiplatelet therapy are needed **to reduce the risk of developing macrovascular disease (ischemic heart disease, peripheral vascular disease, and cerebrovascular disease).**

# Therapy of Diabetes Mellitus

- Hyperglycemia also contributes to **poor wound healing** by compromising white blood cell function and altering capillary function.
- Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are **severe manifestations of poor diabetes control, always requiring hospitalization**.

# Non-pharmacologic Management

- 1. Screening (for the presence of DM).**
- 2. Monitor for:**
  - blood glucose, HbA<sub>1c</sub>, fasting lipid profile, urinary albumin (urine albumin-to-creatinine ratio [UACR]) and glomerular filtration rate (GFR) (creatinine clearance), diabetic neuropathy, and dilated eye examination.**

# Non-pharmacologic Management

## 3. Glycemic goals:

- HbA<sub>1c</sub> goal for males and non-pregnant females of <7%, or of <6.5% without significant hypoglycemia.
- Critically ill (Hospital) glucose: 140-180 mg/dL, or more strict guidelines down to 110-140 mg/dL (without hypoglycemia).
- (*The above percentages may differ depending on the method of HbA<sub>1c</sub> measurement*).

# Non-pharmacologic Management

## 4. Medical nutrition therapy:

- **Weight reduction is recommended for all insulin-resistant, overweight or obese individuals.**
  - Either low-carbohydrate, low-fat, calorie-restricted diets, or Mediterranean diets.**
  - Healthier eating behaviors leading to sustained weight loss over time is more important than a specific diet.**

# Non-pharmacologic Management

- In individuals with type 2 diabetes, ingested protein appears to increase insulin response without increasing plasma glucose concentrations.
- Therefore, carbohydrate sources high in protein should NOT be used to treat or prevent hypoglycemia.
- Saturated fat should be <7% of total calories.

# Non-pharmacologic Management

- **A Mediterranean-style eating pattern**, rich in mono-unsaturated fatty acids (**olive oil**), may benefit glycemic control and reduce CVD risk factors.
- Consider financial and cultural food issues.
- **Discourage bedtime** and **between-meal** snacks, and **set realistic goals**.

# Non-pharmacologic Management

- A diet low in fat is recommended for patients with CVD.
- Avoid a high-protein diet **in patients with nephropathy.**
- Supplement with all of the essential vitamins and minerals.

# Non-pharmacologic Management

## 5. Physical Activity:

- **Aerobic exercise improves insulin sensitivity, modestly improves glycemic control, reduces cardiovascular risk, contributes to weight loss or maintenance, raises HDL-cholesterol and improves well-being.**
- **Physical activity goals include at least 150 min/wk of moderate intensity exercise spread over at least 3 days/week with no more than 2 days off between activities.**

# Non-pharmacologic Management

- Resistance/Strength training is recommended at least 2 times a week **in patients without proliferative diabetic retinopathy, and ischemic heart disease.**

# Non-pharmacologic Management

## 6. Patient Education:

- **It is NOT appropriate to give patients with DM brief instructions and a few pamphlets.**
- **Diabetes education, at initial diagnosis and at ongoing intervals over a life-time, is critical.**
- **Healthy behavior includes: healthy eating, being active, monitoring, taking medication, problem solving, reducing risk, and healthy coping.**

# Non-pharmacologic Management

- The patient must be involved in the decision-making process with knowledge of the disease and associated complications.
- **Emphasize that complications can be prevented or minimized with good glycemic control and managing risk factors for CVD.**
- Motivational interviewing techniques to encourage patients to identify barriers that hinder achieving health goals, and then work to solve them, are essential.

# Other Recommendations

## A. Blood pressure:

- Systolic/diastolic blood pressure should be treated to <140 mm / <90 mm Hg.
- Lower goals <130 mm Hg / <80 mm Hg may be appropriate for younger patients.
- Life-style intervention such as weight loss, and diet including reducing sodium and increasing potassium.
- Initial drug therapy should be with an ACEi or an angiotensin-receptor blocker (ARB).

# Other Recommendations

## B. Dyslipidemia:

- Lifestyle modification focusing on the **reduction of saturated fat, and cholesterol intake; increasing omega-3 fatty acids intake, use of viscous fiber, and plant sterols; weight loss, and increased physical activity should be recommended.**
- Consider the use of **statins** according to risks.

# Other Recommendations

## C. Antiplatelet Therapy:

- Use aspirin (75-162 mg daily) for secondary cardioprotection.

## D. Hospitalized Patients:

- Critically ill: IV insulin protocol.
- Non-critically ill: scheduled subcutaneous insulin with basal and correction coverage.

## E. Psychosocial:

- Assess the patient's psychological and social situation as an ongoing part of the medical management of diabetes.

# Prevention of Diabetes Mellitus

**A. The aim of prevention of type 1 DM is to slow or stop its progression.**

- **Screening for patients at risk is necessary but not easy.**
- **Type 1 DM is a low prevalence disease in children, and the risk of false positives in screening tests is very high.**
- **Numerous clinical trials have not highlighted significant results**
- **The way to find safe and effective preventive therapies is still far.**

# Prevention of Diabetes Mellitus

- Teplizumab, a humanized monoclonal antibody to CD3 on T cells.
- Teplizumab has been approved by FDA as the first drug that mildly delays the onset of type 1 DM in patients 8 years of age or older with preclinical disease.
- Teplizumab prevention of disease progression in patients with newly diagnosed type 1 diabetes is not known.

# Prevention of Diabetes Mellitus

## B. Prevention of type 2 diabetes:

1. The “4 life-style pillars” for the prevention of type 2 diabetes are to:

- a) decrease weight.
- b) increase aerobic exercise.
- c) increase fiber in diet.
- d) decrease fat intake.


# Prevention of Diabetes Mellitus

## 2. Drugs:

- a. **Metformin** therapy **reduces the risk of developing type 2 DM**, especially in obese, <60-year-old patients, and women with prior gestational diabetes mellitus (GDM).
- b. **Rosiglitazone** **reduces the incidence of type 2 diabetes.**
- c. **Acarbose** **decreases progression to type 2 DM.**
- d. **Liraglutide** **decreases progression to type 2 DM.**

# Pharmacologic Therapy (Type 1 DM)

- All patients with type 1 DM require insulin.




Relationship between insulin and glucose over the course of a day.

# Pharmacologic Therapy (Type 1 DM)

- Attempt to mimic normal secretion of insulin.
- One or two injections of insulin daily will in NO way mimic normal physiology, and **therefore, is unacceptable.**
- The timing of insulin onset, peak, and duration of effect must match meal patterns and exercise schedules to achieve adequate blood glucose control throughout the day.

# Insulin



**FIGURE 41-5** Extent and duration of action of various types of insulin as indicated by the glucose infusion rates (mg/kg/min) required to maintain a constant glucose concentration. The durations of action shown are typical of an average dose of 0.2–0.3 U/kg. The durations of regular and NPH insulin increase considerably when dosage is increased.

**Pharmacokinetics of Select Insulins Administered Subcutaneously**

Type of Insulin	Onset (Hours)	Peak (Hours)	Duration (Hours)	Maximum Duration (Hours)	Appearance
<b><i>Rapid acting</i></b>					
Aspart	15-30 min	1-2	3-5	5-6	Clear
Lispro	15-30 min	1-2	3-4	4-6	Clear
Glulisine	15-30 min	1-2	3-4	5-6	Clear
Technosphere <sup>a</sup>	5-10 min	0.75-1	~3	~3	Powder
<b><i>Short-acting</i></b>					
Regular	0.5-1.0	2-3	4-6	6-8	Clear
<b><i>Intermediate acting</i></b>					
NPH	2-4	4-8	8-12	14-18	Cloudy
<b><i>Long acting</i></b>					
Detemir	~2 hours	__ <sup>b</sup>	14-24	20-24	Clear
Glargine (U-100)	~2-3 hours	__ <sup>b</sup>	22-24	24	Clear
Degludec	~2 hours	__ <sup>b</sup>	30-36	36	Clear
Glargine (U-300)	~2 hours	__ <sup>b</sup>	24-30	30	Clear

<sup>a</sup>Technosphere insulin is inhaled.

<sup>b</sup>Glargine is considered “flat” though there may be a slight peak in effect at 8-12 hours, and with detemir at ~8 hours, but both have exhibited peak effects during comparative testing, and these peak effects may necessitate changing therapy in a minority of type 1 DM patients. Degludec and U-300 insulin glargine appear to have less peak effect compared to U-100 insulin glargine.

# Intensive Insulin Regimens

	7 am meal	12 am meal	5 pm meal	Bed time
2 doses (R or rapid acting) + N	R, L, A, Glu + N		R, L, A, Glu + N	
3 doses (R or rapid acting) + N	R, L, A, Glu + N	R, L, A, Glu	R, L, A, Glu + N	
4 doses (R or rapid acting) + N	R, L, A, Glu	R, L, A, Glu	R, L, A, Glu	N
4 doses (R or rapid acting) + N	R, L, A, Glu + N	R, L, A, Glu	R, L, A, Glu	N
4 doses (R or rapid acting) + long acting	R, L, A, Glu	R, L, A, Glu	R, L, A, Glu	G or D
CS-II pump	Adjusted basal + Bolus	Adjusted basal + Bolus	Adjusted basal + Bolus	
3 prandial doses	P added to previous regimens	P added to previous regimens	P added to previous regimens	

A, aspart; CS-II, continuous subcutaneous insulin infusion; D, detemir or degludec; G, glargine; GLU, glulisine; L, lispro; N, NPH; P, pramlintide; R, regular.

# Pharmacologic Therapy (Type 1 DM)

- The simplest regimens that can approximate physiologic insulin release use “split-mixed” injections consisting of a morning dose of an intermediate-acting insulin (NPH) and a “bolus” rapid-acting insulin or regular insulin prior to the morning and evening meals.
- The morning intermediate-acting insulin dose provides basal insulin during the day and provides “prandial” coverage for the midday meal.

# Pharmacologic Therapy (Type 1 DM)

- The evening intermediate-acting insulin dose provides basal insulin throughout the evening and overnight.
- This may be acceptable when patients have fixed timing of meals and carbohydrate intake.
- However, This regimen may NOT achieve good glycemic control overnight without causing nocturnal hypoglycemia.
- Moving the evening NPH dose to bedtime may improve glycemic control and reduce the risk of nocturnal hypoglycemia.

# Pharmacologic Therapy (Type 1 DM)

- **“Basal-bolus” regimens using multiple daily injections may mimic normal insulin physiology, with a combination of intermediate- or long-acting insulin to provide the basal insulin, and a rapid-acting insulin to provide prandial coverage.**
- **Long-acting insulins include insulin detemir, glargine, degludec. ..**

# Pharmacologic Therapy (Type 1 DM)

- **Bolus or prandial insulin can be provided by either regular insulin or rapid-acting insulin analogs: lispro, aspart, or glulisine.**
- **The rapid onset and short duration of action of the rapid-acting insulin analogs more closely replicate normal physiology than does regular insulin.**
- **(Remember that regular insulin is soluble insulin, or crystalline zinc insulin).**

# Pharmacologic Therapy (Type 1 DM)

- **Approximately 50% of total daily insulin replacement should be in the form of basal insulin and the other 50% in the form of bolus insulin, divided between meals.**
- **For new patients, the initial total daily dose is usually 0.5 - 0.6 units/kg/day.**

# Pharmacologic Therapy (Type 1 DM)

- Continuous subcutaneous insulin infusion (CS-II) or insulin pumps using a rapid-acting insulin is **the most sophisticated and precise method for insulin delivery.**
- In highly motivated patients, it achieves excellent glycemic control more than multiple daily injections (MDI).
- Insulin pump therapy may also be paired to **continuous glucose monitoring (CGM)**, which allows calculation of a correct insulin dose, **as well as alert the patient to hypoglycemia and hyperglycemia.**

# Pharmacologic Therapy (Type 1 DM)

- **Insulin pumps require greater attention to details and more frequent self-monitored blood glucose (SMBG) than does a basal-bolus multiple daily injections regimen.**
- **Patients need extensive training on how to use and maintain their pump.**

# Pharmacologic Therapy (Type 1 DM)

- All patients treated with insulin should be instructed how to recognize and treat hypoglycemia.
- At each visit, patients with type 1 DM should be evaluated for hypoglycemia including the frequency and severity of hypoglycemic episodes.

# Pharmacologic Therapy (Type 1 DM)

- Hypoglycemic unawareness may result from autonomic neuropathy or from frequent episodes of hypoglycemia.
- The loss of warning signs of hypoglycemia is a **relative contraindication** to **continued intensive therapy**.

# Pharmacologic Therapy (Type 1 DM)

- Patients who have erratic postprandial glycemic control despite proper insulin dose may benefit from addition of the amylinomimetic drug pramlintide.
- Amylin suppresses endogenous production of glucose in the liver.
- Pramlintide taken prior to each meal can improve postprandial blood glucose control.
- **It is NOT a substitute for bolus insulin.**

# Pharmacologic Therapy (Type 1 DM)

- Pramlintide can NOT be mixed with insulin requiring the patient to take an additional injection at each meal.
- When pramlintide is initiated, the dose of prandial insulin should be reduced by 30 - 50%, to prevent hypoglycemia.

# Pharmacologic Therapy (Type 1 DM)

## **Pramlintide:**

- 1. Slows gastric emptying – mediated by the vagus nerve.**
  - 2. Reduces glucagon secretion.**
  - 3. Promotes satiety or reduces appetite - centrally.**
  - 4. Produces moderate weight loss.**
- Main adverse effects include: Hypoglycemia and GIT disturbances (nausea & vomiting), and anorexia).**

# Pharmacologic Therapy (Type 2 DM)

1. Symptomatic patients may initially require treatment with insulin or combination therapy.
2. All patients should be treated with therapeutic life-style modification.
3. Patients with  $\text{HbA}_{1c} \leq 7.5\%$  are usually treated with metformin (which is unlikely to cause hypoglycemia when given alone).
4. Those with  $\text{HbA}_{1c} > 7.5\%$  but  $< 8.5\%$  could be initially treated with a single agent, or combination therapy.

# Pharmacologic Therapy (Type 2 DM)

5. **Patients with higher initial HbA<sub>1c</sub> will require two agents OR insulin.**
6. **All therapeutic decisions should consider the needs and preferences of the patient, if medically possible.**
7. **Obese patients without contraindications are often started on metformin which is titrated up to 2,000 mg/day. (contraindications: renal dysfunction, congestive cardiac failure, respiratory disease, metabolic acidosis, impaired hepatic function).**

# Pharmacologic Therapy (Type 2 DM)

8. **Non-obese patients are more likely to be insulinopenic, necessitating medications that may increase insulin secretion.**
9. **An insulin secretagogue, such as a sulfonylurea, is often added second.**
  - a) **Sulfonylureas have several potential drawbacks including weight gain and hypoglycemia.**
  - b) **They may not be taken in patients with liver or kidney disease.**
  - c) **They do NOT produce a durable glycemic response.**

# Pharmacologic Therapy (Type 2 DM)

10. Better choices may include Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) and GLP-1 receptor agonists but they have therapeutic and safety limitations.
11. Thiazolidinediones (TZDs) produce a more durable glycemic response and are unlikely to cause hypoglycemia when used alone, but **weight gain, osteoporosis, and the risk of new onset heart failure have limited their use.**

**Healthy eating, weight control, increased physical activity, and diabetes education**

**Initial drug monotherapy**

Efficacy (↓ HbA <sub>1c</sub> )...	Metformin
Hypoglycemia.....	High
Weight.....	Low risk
Side effects.....	Neutral / loss
Costs.....	GI/lactic acidosis
	Low

**Dual Therapy**

**If individualized HbA<sub>1c</sub> target not reached, proceed to two-drug combination**

Efficacy (↓ HbA<sub>1c</sub>)...  
Hypoglycemia.....  
Weight.....  
Side effects.....  
Costs.....

	Metformin +	Metformin +	Metformin +	Metformin +	Metformin +	Metformin +
	SU	TZD	DPP4i	SGLT2 inhibitor	GLP1-RA	Insulin
Efficacy	High	High	Intermediate	Intermediate	High	Highest
Hypoglycemia	Moderate risk	Low risk	Low risk	Low risk	Low risk	High risk
Weight	Gain	Gain	Neutral	Loss	Loss	Gain
Side effects	Hypoglycemia	Edema, HF, Bone	GI	GU, dehydration	GI	Hypoglycemia
Costs	Low	Moderate	High	High	High	Variable

**Triple Therapy**

**If individualized HbA<sub>1c</sub> target not reached after ~3 months, proceed to three-drug combination**  
(order not to denote any preference choice dependent on variety of patient- and disease-specific factors)

SU+ TZD or SGLT2i or DPP4i or GLP1-RA or Insulin	TZD+ SU or SGLT2i or DPP4i or GLP1-RA or Insulin	DPP4i+ SU or TZD or SGLT2i or Insulin	SGLT2i+ SU or TZD Or DPP4i or Insulin	GLP1-RA+ SU or TZD or Insulin	Insulin+ TZD or SGLT2 i or DPP4i or GLP1-RA
---	---	---	---	--	---

**Combination Injectable Therapy**

**If HbA<sub>1c</sub> target not achieved after ~3 months of triple therapy and patient (1) on oral therapy, move to injectables; (2) on GLP-1RA, add basal insulin; (3) on optimally titrated basal insulin, add GLP-1RA or mealtime insulin. In refractory patient consider adding TZD or SGLT2i**

**Basal insulin + Mealtime Insulin or GLP-1 RA**

Drug & class	Dose ( mg)	Duration of action (hours)	Drug	Dose ( mg)	Duration of action (hours)
<b>Sulfonylureas</b>					
Glimepiride	1-8	24	Glipizide	2.5-40	12-24
Glyburide	1.25-20	12-24	Glipizide extended release	5-20	24
Micronized glyburide	1-12	24			
<b>Non-sulfonylureas secretagogues</b>					
Rapaglinide	0.5-4	2-3	Nateglinide	60-120	2-4
<b>Biguanides</b>					
Metformin	500-2500	6-12	Metformin extended release	1500-2000	24
<b>Thiazolidinediones</b>					
Rosiglitazone	4-8	Poorly correlated with half-life. Max effect ~ 4 weeks	Pioglitazone	15-45	Poorly correlated with half-life. Max effect ~ 4 weeks
<b><math>\alpha</math>-glucosidase inhibitors</b>					
Acarbose	25-50	Affects absorption of carbohydrates in a single meal	Miglitol	25-100	Affects absorption of carbohydrates in a single meal
<b>GLP-1 receptor agonists / Incretin mimetics</b>					
Exenatide	5-10 mcg	10	Liraglutide	0.6-1.8	24
<b>DPP-4 inhibitors</b>					
Sitagliptin	100	24	Saxagliptin	2.5-5	24
Linagliptin	5	24			
<b>Amylin mimetics</b>					
Pramlintide	15-60 (type 1 DM) 60 or 120 (type 2 DM)	$C_{max}$ 20 min			
<b>Bile acid sequestrants</b>					
Colesevelam	3750	N/A			

# Pharmacologic Therapy (Type 2 DM)

Treatment selection should be based on multiple factors:

1. A patient who has had diabetes for several years, due to progressive failure of  $\beta$ -cell function, is more likely to require insulin therapy.
2. If the patient has multiple co-morbidities (depression, osteoporosis, CVD, heart failure, recurrent genitourinary infections), some medications may be poor choices based on their potential adverse effects.

# Pharmacologic Therapy (Type 2 DM)

3. If the patient's **postprandial blood glucose** readings are the primary reason for poor control, pick a medication that addresses postprandial blood glucose fluctuations (glinides and  $\alpha$ -glucosidase inhibitors).
4. If the patient's **fasting blood glucose** readings are consistently elevated, a medication that addresses fasting blood glucose would be a better choice.

# Pharmacologic Therapy (Type 2 DM)

- 5. Adverse effect profile, contraindications, hypoglycemia potential, effect on body weight, tolerability by the patient, and cost should be considered when selecting therapy.**
- 6. Motivation, resources, and potential difficulties with adherence should also influence treatment selection.**

# Pharmacologic Therapy (Type 2 DM)

7. If the patient is an **older adult**, the risk of hypoglycemia and other adverse effects increases. These factors **should influence medication choices, doses and HbA1c goals**.
8. It is unlikely that any one drug class will **arrest  $\beta$ -cell failure**, necessitating combination therapy.
  - **The combination of a TZD and GLP-1 receptor agonist is a good one:**

# Pharmacologic Therapy (Type 2 DM)

- a) TZDs reduce apoptosis of  $\beta$ -cells.
- b) GLP-1 receptor agonists augment pancreatic function.
- Metformin, pioglitazone, and exenatide are promising.

# Glucagon-like peptide-1 (GLP-1) from the GIT

1. It enhances insulin release in response to an ingested meal.
  2. It suppresses glucagon secretion.
  3. It delays gastric emptying.
  4. It decreases appetite.
- It is degraded by dipeptidyl peptidase-4 (DPP-4).

# Glucagon-like peptide-1 (GLP-1) from the GIT

## Glucagon-like peptide-1 agonists:

- **Exenatide** - twice daily subcutaneously.
- **Exenatide** - once weekly subcutaneously.
- **Liraglutide** - once daily subcutaneously.
- **Semaglutide** - once weekly subcutaneously, daily orally.

## Dual Agonists activate both the Glucose-dependent Insulinotropic polypeptide (GIP) and GLP-1 receptors:

- **Tirzepatide** - once weekly subcutaneously.

# **Glucagon-like peptide-1 (GLP-1) from the GIT**

- **The GLP-1 receptor agonists, with or without metformin based on glycemic needs, are appropriate initial therapy for patients with type 2 diabetes mellitus (T2DM) with or at high risk for atherosclerotic cardiovascular disease (ASCVD)**
- **They are generally recommended as a second or third-line option as add-on to metformin therapy in patients with T2DM who do not have ASCVD**

# Glucagon-like peptide-1 (GLP-1) from the GIT

- These drugs reduce major adverse cardiovascular events (MACE; e.g., non-fatal myocardial infarction or non-fatal stroke, CV mortality)
- Both GLP-1 receptor agonists and GIP/ GLP-1 dual agonists **promote weight loss** and may be used for weight management
- Gastrointestinal side effects are the most common adverse reactions leading to discontinuation of these medications **(?!)**

# Pharmacologic Therapy (Type 2 DM)

## Exenatide:

- It is an analogue of GLP-1, acts as agonist at GLP-1 receptors.
- Used as adjunctive therapy in patients with type 2 diabetes treated with metformin, or metformin plus sulfonylureas who still have suboptimal glycemic control.
- Delays gastric emptying.
- Suppresses postprandial glucagon release.

# Pharmacologic Therapy (Type 2 DM)

- It increases insulin secretion in a glucose-dependent manner.
- It increases in beta-cell mass, from decreased beta-cell apoptosis.
- May increased beta-cell formation.
- Suppresses appetite.
- Associated with weight loss.

# Pharmacologic Therapy (Type 2 DM)

## Adverse effects:

1. **Nausea, vomiting, diarrhea:** major adverse effect is nausea (45%), which is dose-dependent and declines with time.
  2. **Acute pancreatitis.**
  3. **Renal impairment and acute renal injury.**
- Not associated with hypoglycemia unless used in combination.

# Pharmacologic Therapy (Type 2 DM)

- With time some patients with type 2 DM become relatively insulinopenic necessitating **insulin therapy**.
- In these patients **use insulin injections at bedtime (intermediate- or long-acting basal insulin) while continuing to use oral agents or GLP-1 receptor agonists for control during the day.**

# Pharmacologic Therapy (Type 2 DM)

- **This strategy is associated with less weight gain, equal efficacy, and lower risk of hypoglycemia when compared to starting prandial insulin or split-mix twice daily insulin regimens.**
- **Any modification of this strategy should depend on fasting and posprandial glucose monitoring, HbA<sub>1c</sub> monitoring, and times of development of hypoglycemia.**

# Dipeptidyl peptidase-4 (DPP-4) inhibitors

- Inhibit DPP-4, the enzyme that degrades incretin hormones.
- Prolong the half-life of endogenous GLP-1.
- Decrease postprandial glucose levels.
- Decrease glucagon concentration.
- Increase circulating GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) and thus, insulin concentrations in a glucose-dependent manner.

# Dipeptidyl peptidase-4 (DPP-4) inhibitors

- Include **sitagliptin**, saxagliptin, luragliptin, linagliptin, and alogliptin.
- Used for type 2 DM orally
- Most commonly used in combination with a TZD or metformin, or sulfonylureas.
- May be used as monotherapy.
- **Dosage should be reduced in patients with impaired renal function**
- Weight neutral.

# (DPP-4) inhibitors

## Adverse effects:

1. **Nasopharyngitis, upper respiratory infections, headaches**
  2. **Hypoglycemia** when the drug is combined with insulin secretagogues or insulin.
  3. **Acute pancreatitis** which may be fatal.
  4. Allergic reactions - angioedema.
  5. GIT: nausea, diarrhoea and abdominal pain.
- **FDA warning:** increase heart failure risk and severe joint pain.

# Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors

- SGLT2 is the main transporter for glucose re-absorption in the proximal tubules (90%).
- Inhibitors include **canagliflozin, dapagliflozin, and others** which increases urinary glucose loss.
- May be used in type 2 diabetes.

# (SGLT2) Inhibitors

**Benefits:** (According to [“The National Kidney Foundation, USA”](#))

- **SGLT2 inhibitors are effective at slowing the progression of kidney disease, reducing heart failure, and lowering the risk of kidney failure and death in people with kidney disease and type 2 diabetes.**
- **SGLT2 inhibitors may protect the kidneys of people with CKD who do not have diabetes.**
- **May also reduce the risk for heart disease in people with a history of heart disease.**

# (SGLT2) Inhibitors

## Adverse effects:

Mild: polyuria and thirst

## Severe:

1. Increased incidence of genital and urinary tract infections. FDA warning
2. Intravascular volume contraction and hypotension ← osmotic diuresis.
3. Decreased bone mineral density at the lumbar spine and the hip.

# **(SGLT2) Inhibitors**

- 4. Fractures due to osteoporosis and/or falls secondary to hypotension.**
- 5. Should not be used in patients prone to diabetic ketoacidosis.**

# Effect of Some Antidiabetics on Body Weight

<b>Drug</b>	<b>Effect on body weight</b>
<b>Insulin</b>	<b>Weight gain</b>
<b>Sulfonylureas</b>	<b>Weight gain</b>
<b>Meglitinides</b>	<b>Weight gain</b>
<b>Metformin</b>	<b>No change or reduce</b>
<b>Thiazolidinediones</b>	<b>Weight gain + fluid retention</b>
<b>Amylin Analogues -pramlintide</b>	<b>Moderate weight loss</b>
<b>GLP-1 analogues (exenatide)</b>	<b>Weight loss</b>
<b>DPP-4 inhibitors (sitagliptin)</b>	<b>Weight neutral</b>

# Special Populations (**Children and Adolescents with Type 2 DM**)

- **Type 2 DM is increasing in adolescence probably caused by obesity and physical inactivity.**
- **Need extraordinary efforts on life-style modification measures.**
- **If failed, use metformin, sulfonylureas (or TZDs) or any combination of these that may improve glycemic control.**

# Special Populations (**Children and Adolescents with Type 2 DM**)

- **Insulin therapy is the standard of care when glycemic goals can NOT be achieved or maintained with metformin and sulfonylurea.**

# Special Populations (**Elderly patients with Type 2 DM**)

- Consideration of the **risks of hypoglycemia**, the extent of co-morbidities, self-care, nutritional status, social support, falls risk, mental status, and life expectancy should all influence glycemic goals and treatment selection.
- **Avoidance of both hypo- and hyperglycemia is extremely important.**

# Special Populations (**Elderly patients with Type 2 DM**)

- **Elderly patients may have an altered presentation of hypoglycemia because of loss of autonomic nerve function with age.**
- **DPP-4 inhibitors (**Sitagliptin**), shorter-acting insulin secretagogues (**rapaglinide**), low-dose sulfonylureas, or  $\alpha$ -glucosidase inhibitors may be used.**

# Special Populations (**Elderly patients with Type 2 DM**)

- **DPP-4 inhibitors or  $\alpha$ -glucosidase inhibitors have low risk of hypoglycemia.**
- **Metformin may be used at low doses if  $Cl_{cr}$  is  $> 30$  mL/min/1.73 m<sup>2</sup>.**
- **Simple insulin regimens with daily basal insulin may be appropriate.**

# Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

- **These are true emergencies.**
- **Insulin given by continuous IV infusion (regular insulin = soluble insulin = crystalline zinc insulin) to restore the patient's metabolic status is the cornerstone of therapy.**
- **Pay attention to volume deficits, electrolyte disturbances, and acidosis.**
- **Treat the precipitating causes.**

# Hospitalization for Intercurrent Medical Illness

- Patients on oral agents may need transient therapy with insulin to achieve adequate glycemic control during hospitalization.
- **It is important to stop metformin in all patients who arrive in acute care settings as contraindications to metformin are prevalent in hospitalized patients (renal dysfunction, hypoxia..).**

# Perioperative Management

- **Patients who require surgery may experience worsening of glycemia similar to those admitted to hospital for a medical illness.**
- **Acute stress increases counter-regulatory hormones.**
- **Therapy should be individualized based on the type of DM, nature of the surgical procedure, previous therapy, and metabolic control prior to the procedure.**

# Perioperative Management

- **Patients on oral agents may need to be transiently switched to insulin to control blood glucose, preferably as continuous insulin infusions.**
- **Metformin should be discontinued temporarily after any major surgery until it is clear that the patient is hemodynamically stable and normal renal function is documented.**